Bioactivation, protein haptenation, and toxicity of sulfamethoxazole and dapsone in normal human dermal fibroblasts

Toxicology and Applied Pharmacology

Volumn 215, Issue 2, 2006, Pages 158-167

  Bhaiya, Payal ^a   Roychowdhury, Sanjoy ^a   Vyas, Piyush M ^a   Doll, Mark A ^b   Hein, David W ^b   Svensson, Craig K ^a  

^a UNIVERSITY OF IOWA   (United States)

^b University of Louisville School of Medicine   (United States)

Author keywords

Cutaneous drug reactions; Fibroblasts; N acetyltransferase; Protein haptenation; Sulfonamides; Toxicity

Indexed keywords

ACETYLDAPSONE; ACYLTRANSFERASE; AROMATIC AMINE; ARYLAMINE ACETYLTRANSFERASE; CELL PROTEIN; DAPSONE; DRUG METABOLITE; GLUTATHIONE; HAPTEN; HYDROXYLAMINE; MESSENGER RNA; N HYDROXYDAPSONE; PROTEIN; REACTIVE OXYGEN METABOLITE; SULFAMETHOXAZOLE; SULFAMETHOXAZOLE HYDROXYLAMINE; SULFONE; UNCLASSIFIED DRUG;

ACETYLATION; ARTICLE; CONCENTRATION RESPONSE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; DETOXIFICATION; DRUG ACTIVITY; DRUG SENSITIVITY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EVALUATION; HUMAN; HUMAN CELL; KERATINOCYTE; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN METABOLISM; SKIN FIBROBLAST;

ANTI-INFECTIVE AGENTS; ARYLAMINE N-ACETYLTRANSFERASE; CELLS, CULTURED; DAPSONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ERUPTIONS; EPIDERMIS; FIBROBLASTS; HAPTENS; HUMANS; ISOENZYMES; OXIDATIVE STRESS; RNA, MESSENGER; SULFAMETHOXAZOLE;

EID: 33746871427     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2006.02.006     Document Type: Article

References (56)

1. Cribb A.E., and Spielberg S.P. Sulfamethoxazole is metabolized to the hydroxylamine in humans. Clin. Pharmacol. Ther. 51 (1992) 522-526
2. Cribb A.E., Nakamura H., Grant D.M., Miller M.A., and Spielberg S.P. Role of polymorphic and monomorphic human arylamine N-acetyltransferases in determining sulfamethoxazole metabolism. Biochem. Pharmacol. 45 (1993) 1277-1282
3. 4-hydroxylation of sulfamethoxazole by cytochrome P450 of the cytochrome P4502C subfamily and reduction of sulfamethoxazole hydroxylamine in human and rat hepatic microsomes. Drug Metab. Dispos. 23 (1995) 406-414
4. Cribb A.E., Lee B.L., Trepanier L.A., and Spielberg S.P. Adverse reactions to sulphonamide and sulphonamide-trimethoprim antimicrobials: clinical syndromes and pathogenesis. Adverse Drug React. Toxicol. Rev. 15 (1996) 9-50
5. Cribb A.E., Nuss C.E., Alberts D.W., Lamphere D.B., Grant D.M., Grossman S.J., and Spielberg S.P. Covalent binding of sulfamethoxazole reactive metabolites to human and rat liver subcellular fractions assessed by immunochemical detection. Chem. Res. Toxicol. 9 (1996) 500-507
6. Cucinelli S.A., Israili Z.H., and Dayton P.G. Microsomal N-oxidation of dapsone as a cause of methemoglobin formation in human red cells. Am. J. Trop. Med. Hyg. 21 (1972) 322-331
7. Eltom S.E., Larsen M.C., and Jefcoate C.R. Expression of CYP1B1 but not CYP1A1 by primary cultured human mammary stromal fibroblasts constitutively and in response to dioxin exposure: role of the Ah receptor. Carcinogenesis 19 (1998) 1437-1444
8. Engler O.B., Strasser I., Naisbitt D.J., Cerny A., and Pichler W.J. A chemically inert drug can stimulate T cells in vitro by their T cell receptor in non-sensitised individuals. Toxicology 197 (2004) 47-56
9. Gelber R., Peters J., Gordon G., Glazko A., and Levy L. The polymorphic acetylation of dapsone in man. Clin. Pharmacol. Ther. 12 (1971) 225-238
10. Gordon G.R., Murray J.F., Peters J.H., Gelber R.H., and Jacobson R.R. Studies on the urinary metabolites of dapsone in man. Int. J. Lepr. 47 (1979) 681-682
11. Gruchalla R. Drug metabolism, danger signals, and drug-induced hypersensitivity. J. Allergy Clin. Immunol. 108 (2001) 475-488
12. Hein D.W., Doll M.A., Fretland A.J., Leff M.A., Webb S.J., Xiao G.H., Devanaboyina U.-S., Nangju N.A., and Feng Y. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol., Biomarkers Prev. 9 (2000) 29-42
13. Husain A., Barker D.F., States J.C., Doll M.A., and Hein D.W. Identification of the major promoter and non-coding exons of the human arylamine N-acetyltransferase 1 gene (NAT1). Pharmacogenetics 14 (2004) 397-406
14. Kawakubo Y., Yamazoe Y., Kato R., and Nishikawa T. High capacity of human skin for N-acetylation of arylamines. Skin Pharmacol. 3 (1990) 180-185
15. Kawakubo Y., Merk H.F., Al Masaqudi T., Sieben S., and Blomeke B. N-acetylation of paraphenylenediamine in human skin and keratinocytes. J. Pharmacol. Exp. Ther. 292 (2000) 150-155
16. Leccia M.-T., Richard M.-J., Joanny-Crisci F., and Beani J.-C. UV-A1 cytotoxicity and antioxidant defence in keratinocytes and fibroblasts. Eur. J. Dermatol. 8 (1998) 478-482
17. Leff M.A., Epstein P.N., Doll M.A., Fretland A.J., Devanaboyina U.S., Rustan T.D., and Hein D.W. Prostate-specific human N-acetyltransferase 2 (NAT2) expression in the mouse. J. Pharmacol. Exp. Ther. 290 (1999) 182-187
18. Manchanda T., Hess D., Dale L., Ferguson S.G., and Rieder M.J. Haptenation of sulfonamide reactive metabolites to cellular proteins. Mol. Pharmacol. 62 (2002) 1011-1026
19. Matzinger P. Tolerance, danger, and the extended family. Annu. Rev. Immunol. 12 (1994) 991-1045
20. Mauri-Hellweg D., Bettens F., Mauri D., Brander C., Hunziker T., and Pichler W.J. Activation of drug-specific CD4+ and CD8+ T cells in individuals allergic to sulfonamides, phenytoin, and carbamazepine. J. Immunol. 155 (1995) 462-472
21. May D.G., Porter J.A., Uetrecht J.P., Wilkinson G.R., and Branch R.A. The contribution of N-hydroxylation and acetylation to dapsone pharmacokinetics in normal subjects. Clin. Pharmacol. Ther. 48 (1990) 619-627
22. Mitra A.K., Thummel K.E., Kalhorn T.F., Kharasch E.D., Unadkat J.D., and Slattery J.T. Metabolism of dapsone to its hydroxylamine by CYP2E1 in vitro and in vivo. Clin. Pharmacol. Ther. 58 (1995) 556-566
23. Naisbitt D.J., Farrell J., Gordon S.F., Maggs J.L., Burkhart C., Pichler W.J., Pirmohamed M., and Park B.K. Covalent binding of the nitroso metabolite of sulfamethoxazole leads to toxicity and major histocompatibility complex-restricted antigen presentation. Mol. Pharmacol. 62 (2002) 628-637
24. Nassif A., Bensussan A., Dorothee G., Mami-Chouaib F., Bachot N., Bagot M., Boumsell L., and Roujeau J.C. Drug specific cytotoxic T-cells in the skin of lesions of a patient with toxic epidermal necrolysis. J. Invest. Dermatol. 118 (2002) 728-733
25. Palamanda J.R., Hickman D., Ward A., Sim E., Romkes-Sparks M., and Unadkat J.D. Dapsone acetylation by human liver arylamine N-acetyltransferases and interaction with antiopportunistic infection drugs. Drug Metab. Dispos. 23 (1995) 473-477
26. Park B.K., and Kitteringham N.R. Drug-protein conjugation and its immunological consequences. Drug Metab. Rev. 22 (1990) 87-144
27. Park B.K., Coleman J.W., and Kitteringham N.R. Drug disposition and drug hypersensitivity. Biochem. Pharmacol. 36 (1987) 581-590
28. Park B.K., Pirmohamed M., and Kitteringham N.R. Idiosyncratic drug reactions: a mechanistic evaluation of risk factors. Br. J. Clin. Pharmacol. 34 (1992) 377-395
29. Park B.K., Pirmohamed M., and Kitteringham N.R. Role of drug disposition in drug hypersensitivity: a chemical, molecular, and clinical perspective. Chem. Res. Toxicol. 11 (1998) 969-988
30. Park B.K., Kitteringham N.R., Powell H., and Pirmohamed M. Advances in molecular toxicology-Towards understanding idiosyncratic drug toxicity. Toxicology 153 (2000) 39-60
31. Pascale R., Ruggiu M.E., Simile M.M., Daino L., Vannini G., Seddaiu M.A., Satta G., and Feo F. Dependence of benzo(a)pyrene metabolism on NADPH pool in normal and glucose-6-phosphate dehydrogenase deficient human fibroblasts. Res. Commun. Chem. Pathol. Pharmacol. 69 (1990) 361-364
32. Picardo M., Zompetta C., Marchese C., et al. Paraphenylenediamine, a contact allergen, induces oxidative stress and ICAM-1 expression in human keratinocytes. Br. J. Dermatol. 126 (1992) 450-455
33. Pichler W.J. Pharmacological interaction of drugs with antigen-specific immune receptors: the p-i concept. Curr. Opin. Allergy Immunol. 2 (2002) 301-305
34. Pichler W.J. Delayed drug hypersensitivity reactions. Ann. Intern. Med. 139 (2003) 683-693
35. Pichler W.J., Yawalkar N., Britschgi M., Depta J.P.H., Strasser I., Schmid S., Kuechler P., and Naisbitt D. Cellular and molecular pathophysiology of cutaneous drug reactions. Am. J. Clin. Dermatol. 3 (2002) 229-238
36. Reilly T.P., and Ju C. Mechanistic perspectives on sulfonamide-induced cutaneous drug reactions. Curr. Opin. Allergy Clin. Immunol. 2 (2002) 307-315
37. Reilly T.P., Lash L.H., Doll M.A., Hein D.W., Woster P.M., and Svensson C.K. A role for bioactivation and covalent binding within epidermal keratinocytes in sulfonamide-induced cutaneous drug reactions. J. Invest. Dermatol. 114 (2000) 1164-1173
38. Rieder M.J., Uetrecht J., Shear N.H., and Spielberg S.P. Synthesis and in vitro toxicity of hydroxylamine metabolites of sulfonamides. J. Pharmacol. Exp. Ther. 244 (1988) 724-728
39. Rodrigues-Lima F., Cooper R.N., Goudeau B., Atmane N., Chamagne A.-M., Butler-Browne G., Sim E., Vicart P., and Dupret J.-M. Skeletal muscles express the xenobiotic-metabolizing enzyme arylamine N-acetyltransferase. J. Histochem. Cytochem. 51 (2003) 789-796
40. Roychowdhury S., Vyas P.M., Reilly T.P., Gaspari A.A., and Svensson C.K. Characterization of the formation and localization of sulfamethoxazole- and dapsone-associated drug-protein adducts in human epidermal keratinocytes. J. Pharmacol. Exp. Ther. 314 (2005) 43-52
41. Saeki M., Saito Y., Nagano M., Teshima R., Ozawa S., and Sawada J.-I. mRNA expression of multiple cytochrome P450 isozymes in four types of cultured skin cells. Int. Arch. Allergy Immunol. 127 (2002) 333-336
42. Schnyder B., Burkhart C., Schnyder-Frutig K., von Greyerz S., Naisbitt D.J., Pirmohamed M., Park B.K., and Pichler W.J. Recognition of sulfamethoxazole and its reactive metabolites by drug-specific CD4+ T cells from allergic individuals. J. Immunol. 164 (2000) 6647-6654
43. Shear N.H., and Spielberg S.P. In vitro evaluation of a toxic metabolite of sulfadiazine. Can. J. Physiol. Pharmacol. 63 (1985) 1370-1372
44. Stanley L.A., Coroneos E., Cuff R., Hickman D., Ward A., and Sim E. Immunochemical detection of arylamine N-acetyltransferase in normal and neoplastic bladder. J. Histochem. Cytochem. 44 (1996) 1059-1067
45. Svensson C.K. Do arylhydroxylamine metabolites mediate the idiosyncratic reactions associated with sulfonamides and sulfones?. Chem. Res. Toxicol. 16 (2003) 1034-1043
46. Svensson C.K., Cowen E.W., and Gaspari A.A. Cutaneous drug reactions. Pharmacol. Rev. 53 (2001) 357-379
47. Uetrecht J.P. Idiosyncratic drug reactions: possible role of reactive metabolites generated by leukocytes. Pharm. Res. 6 (1989) 265-273
48. Uetrecht J.P. The role of leukocyte-generated reactive metabolites in the pathogenesis of idiosyncratic drug reactions. Drug Metab. Rev. 24 (1992) 299-366
49. Uetrecht J.P. New concepts in immunology relevant to idiosyncratic drug reactions: the "Danger Hypothesis" and innate immune system. Chem. Res. Toxicol. 12 (1999) 387-395
50. Upton A., Johnson N., Sandy J., and Sim E. Arylamine N-acetyltransferases-of mice, men and microorganisms. Trends Pharmacol. Sci. 22 (2001) 140-146
51. van der Ven A.J., Mantel M.A., Vree T.B., Koopmans P.P., and van der Meer J.W. Formation and elimination of sulphamethoxazole hydroxylamine after oral administration of sulphamethoxazole. Br. J. Clin. Pharmacol. 38 (1994) 147-150
52. van der Ven A.J., Vree T.B., van Ewijk-Beneken Kolmer E.W., Koopmans P.P., and van der Meer J.W. Urinary recovery and kinetics of sulphamethoxazole and its metabolites in HIV-seropositive patients and healthy volunteers after a single oral dose of sulphamethoxazole. Br. J. Clin. Pharmacol. 39 (1995) 621-625
53. Vyas P.M., Roychowdhury S., Woster P.M., and Svensson C.K. Reactive oxygen species generation and its role in the differential cytotoxicity of the arylhydroxylamine metabolites of sulfamethoxazole and dapsone in normal human epidermal keratinocytes. Biochem. Pharmacol. 70 (2005) 275-286
54. Windmill K., Gaedigk A., Hall P., Samaratunga H., Grant D., and McManus M. Localization of N-acetyltransferases NAT1 and NAT2 in human tissues. Toxicol. Sci. 54 (2000) 19-29
55. Zang Y., Zhao S., Doll M.A., States J.C., and Hein D.W. The T341C (Ile114Thr) polymorphism of N-acetyltransferase 2 yields slow acetylator phenotype by enhanced protein degradation. Pharmacogenetics 114 (2004) 717-723
56. Zanni M., von Greyerz S., Schnyder B., Brander K., Frutig K., Hari Y., Valitutti S., and Pichler W. HLA-restricted, processing- and metabolism-independent pathway of drug recognition by human αβ T lymphocytes. J. Clin. Invest. 102 (1998) 1591-1598